Potential public health impact of the adjuvanted recombinant zoster vaccine among people aged 50 years and older in Beijing
Herpes zoster (HZ) is a painful, unilateral rash which occurs upon reactivation of latent varicella zoster virus due to age-related immunity decline or immuno-suppression. In 2019, the recombinant zoster vaccine (RZV) was the first vaccine to be approved in China for HZ prevention. This study aimed...
Saved in:
Main Authors: | Christa Lee (Author), Ning Jiang (Author), Haiwen Tang (Author), Chiyu Ye (Author), Yanfei Yuan (Author), Desmond Curran (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2021-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Lifetime risk of herpes zoster in the population of Beijing, China
by: Christa Lee, et al.
Published: (2023) -
Cost-Effectiveness of the Adjuvant Recombinant Zoster Vaccine in Japanese Adults Aged 65 Years and Older
by: Makoto Shiragami, et al.
Published: (2019) -
The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults ≥ 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trials
by: Joon Hyung Kim, et al.
Published: (2021) -
Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live
by: Desmond Curran, et al.
Published: (2019) -
Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review
by: Nikolaos Giannelos, et al.
Published: (2023)